Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents


ABSTRACT: We have previously shown that T-lymphocytes from clinically glucocorticoid (GC) resistant asthmatics are more refractory to dexamethasone suppression in vitro than those of GC sensitive asthmatics. We wished to extend these observations to compare three GCs used topically for asthma therapy (budesonide, beclomethasone dipropionate and fluticasone 17α-propionate) and three immunosuppressive drugs (cyclosporin A, FK506 (tacrolimus) and mycophenolate mofetil) with dexamethasone for their antiproliferative effects on T-lymphocytes from GC sensitive and resistant asthmatics, and also to compare the rates of steroid metabolism by T-lymphocytes from these patients.

Antiproliferative activity of the drugs was measured on peripheral blood T-lymphocytes activated with phytohaemagglutinin (PHA) and anti-CD3 antibody in vitro. The rates of total steroid metabolism and 20α-hydroxylation by T-cell homogenates were measured using radiolabelled progesterone as an established probe substrate.

Over a wide concentration range, T-lymphocytes from GC resistant asthmatics were significantly less inhibited by all four GCs as compared with cells from GC sensitive asthmatics. The median inhibitory concentrations (IC50) for inhibition of T-lymphocytes from the GC resistant asthmatics exceeded those likely to be achieved therapeutically by systemic administration (although higher concentrations might in theory be achieved locally in the bronchial mucosa by inhaled administration). In contrast, all three immunosuppressive drugs at putative therapeutic concentrations inhibited T-lymphocytes both from GC sensitive and resistant asthmatics with equivalent potency. The rates of total metabolism and 20α-hydroxylation of steroid by homogenates of T-lymphocytes from GC sensitive and resistant asthmatics were equivalent.

Thus, relative GC resistance in T-lymphocytes from GC resistant as compared with sensitive asthmatics is: 1) manifest with GC molecules of variable molecular structure; 2) not accompanied by elevated intracellular metabolism of steroids; and 3) overcome by immunosuppressive drugs which inhibit T-lymphocytes by non-GC-mediated mechanisms. We conclude that current anti-asthma glucocorticoids at therapeutic concentrations are unlikely to be of benefit for the therapy of glucocorticoid resistant asthma, and that other immunosuppressive drugs may have potential as therapeutic agents in these patients.


Over the past few years, studies have accumulated in support of a role for T-lymphocytes in the pathogenesis of asthma. Elevated numbers of activated T-lymphocytes were identified in the bronchial mucosa, bronchoalveolar lavage (BAL) fluid, and peripheral blood of asthmatics as compared with controls [1–5]. Peripheral blood T-lymphocyte activation was reduced after glucocorticoid (GC) therapy of severe asthmatics to a degree which correlated with the extent of clinical improvement [5]. Cells both in the bronchial mucosa and BAL fluid of patients with asthma have been shown to synthesize messenger ribonucleic acid (mRNA) encoding cytokines, which are relevant to eosinophil accumulation and activation, a cardinal feature of asthma [6, 7]. In a controlled trial, GC but not placebo therapy of asthmatics resulted in clinical improvement and a reduction in the percentages of BAL cells expressing these cytokines [8].

These observations indicate that GCs exert their anti-asthma activity, at least partly, by inhibition of activated T-lymphocytes. There exists, however, a subset of asthmatics who respond poorly or not at all to GC therapy [9, 10]. Although this phenomenon is relatively uncommon, an understanding of the mechanisms involved may provide important information regarding the antiasthma effects of GCs and why they fail in some
patients. Furthermore, GC resistance poses a therapeutic problem, since no equally effective anti-inflammatory therapy is currently available.

We and others have shown that GC resistance in asthma is not attributable to altered GC pharmacokinetics [10, 11]. The clinical sensitivity of asthmatics to GC therapy can be correlated with the sensitivity of their peripheral blood T-lymphocytes to GC inhibition of proliferation and cytokine synthesis in vitro [10, 12, 13]. Thus, peripheral blood T-lymphocytes from GC resistant asthmatics show a defective response to GCs in vitro.

Glucocorticoids act by binding to and activating a specific cytosolic receptor, which translocates to the nucleus and binds as a dimer to specific sites on cellular deoxyribonucleic acid (DNA) (GC response elements) situated upstream of the promoter regions of GC-responsive genes, modulating expression of these genes [14]. In T-lymphocytes, GCs inhibit transcription of cytokines, including the growth factor interleukin-2 (IL-2). Although we [10], and others [15], have reported a reduced receptor binding affinity of GCs in T-lymphocytes from GC resistant asthmatics, which may be cytokine-induced [16], it seems unlikely that these small differences in affinity could account entirely for the profound reductions in GC responsiveness observed in peripheral blood T-lymphocytes from resistant patients [10]. Furthermore, chemical mutational analysis shows no evidence for structural abnormalities of the GC receptor gene in sensitive and resistant asthmatics [17]. All of this evidence suggests that GC resistance may result either from abnormal metabolism of GC within the resistant T-lymphocytes, or from a reduced capacity of the activated GC receptor to bind to response elements within these cells. Some evidence in support of the latter possibility has recently been reported [18]. Investigation of the former possibility is the subject of the present study.

To investigate this possibility, we first compared several GCs used for asthma therapy (budesonide, beclomethasone dipropionate and fluticasone 17α-propionate) with dexamethasone for their inhibitory effects on the proliferation of peripheral blood T-lymphocytes from GC sensitive and resistant asthmatics activated by phytohaemagglutinin (PHA) and anti-CD3 antibodies. We hypothesized that, if GC resistance arises from heightened metabolism of GCs in T-lymphocytes, GCs of different molecular structures might be metabolized at different rates in "resistant" T-lymphocytes, resulting in different degrees of inhibition of these cells as compared with "sensitive" T-lymphocytes. Secondly, we compared the activity of the enzyme 20α-hydroxysteroid dehydrogenase (20α-HSDH) in peripheral blood T-lymphocytes from GC sensitive and resistant asthmatics. Previous evidence [19, 20] has suggested that this enzyme is rate-limiting for GC metabolism in T-lymphocytes, and, furthermore, that its activity was higher in T-lymphocytes relatively resistant to GC. We hypothesized that this enzyme shows greater activity in T-lymphocytes from GC resistant as compared with sensitive asthmatics. Finally, we compared the inhibitory effects of the immunosuppressive drugs, FK506 (tacrolimus) and mycophenolate mofetil, on T-lymphocytes from GC sensitive and resistant asthmatics. We hypothesized that, as we have previously reported in the case of cyclosporin A (CsA) [21, 22], these non-GC anti-T-cell drugs inhibit T-lymphocytes from GC sensitive and resistant asthmatics with equivalent potency.

Methods

Patient selection

Patients with moderate to severe asthma (forced expiratory volume in one second (FEV1) ≤70% predicted despite high-dose inhaled GC therapy) were characterized clinically as sensitive or resistant to oral GC therapy according to their FEV1 response to orally administered prednisolone [10, 22]. After a run-in period of 7 days, in which it was established that all patients had stable asthma (defined as <5% variability in morning prebronchodilator peak expiratory flow rate (PEFR) measurements), baseline FEV1 (prebronchodilator) was measured in all patients with a dry bellows spirometer (Vitalograph, Buckingham, UK). The patients were then prescribed oral prednisolone, 20 mg daily, and FEV1 (prebronchodilator) was remeasured after 7 days at the same time of day. Inhaled GC therapy was continued unchanged. If the FEV1 had not improved by >30% of baseline, patients were prescribed prednisolone, 40 mg daily, for an additional 7 days. Consumption of tablets was verified by careful tablet counting by the attending physician rather than by measurement of plasma prednisolone concentrations as in previous studies [10], since we had clearly shown in these studies that GC resistance is not attributable to poor compliance, and all the subjects in the present study were highly motivated to comply with the protocol. Patients who showed an increase in prebronchodilator FEV1 of ≥15% from baseline after this 14 day course of oral GC therapy were classified as sensitive, the remainder were classified as resistant.

Seven sensitive and nine resistant patients were recruited for the present study (table 1). Informed consent was obtained from all patients prior to participation in the study, which was approved by the Ethics Committee of the Royal Brompton Hospital. All patients remained afebrile throughout the study, had normal chest radiographic films and did not suffer from any chronic disease other than asthma. They were taking no medication other than that specified in table 1. In selecting patients, strict criteria were invoked for the diagnosis of asthma and to exclude patients with irreversible airways obstruction. Thus, all patients were required to demonstrate reversibility of ≥15% in their peak expiratory flow rate or FEV1 after administration of inhaled β2-agonist (nebulized salbutamol 5 mg). Smokers were excluded.

Cell culture

Stock solutions were prepared as follows. Appropriate dilutions were made up in RPMI-1640 (Gibco, Paisley, UK) supplemented with L-glutamine, 2 mmol·L⁻¹ (Gibco), and 5% v/v heat-inactivated foetal bovine serum (Gibco).
This supplemented medium (hereafter referred to as "medium") was used for all cell culture procedures. Phytohaemagglutinin (PHA-P; Sigma, Poole, UK) was dissolved (100 mg·mL-1) in medium, sterile filtered, stored in aliquots at -20°C and added to cultured cells at a final concentration of 5 µg·mL-1. Anti-CD3 murine monoclonal antibody (UCHT-1; a kind gift from D. Cantrell) was dissolved (1 mg·mL-1) in medium, stored at -80°C and added in liquid phase to cultured cells at a final concentration of 500 ng·mL-1. Dexamethasone (Sigma), budesonide (Sigma), beclomethasone dipropionate (Sigma), mycophenolate mofetil (Roche Products Ltd, UK) and FK506 (tacrolimus; Fujisawa Co. Ltd, UK) were dissolved in ethanol, and fluticasone 17α-propionate (Glaxo, UK) dissolved in dimethylacetamide to stock concentrations of 10-2 mol·L-1. Cyclosporin A oily suspension (100 mg·mL-1; Sandoz, Switzerland) was dissolved in ethanol, and then in medium to a stock concentration of 10-4 mol·L-1. Aliquots of stock solutions were stored in glass vials at -20°C. Serial 10 fold dilutions of drugs were made up at the time of each experiment by dissolving the stock solutions in medium and sterile-filtering through a 0.22 µm pore size filter as appropriate. The same stock solutions were used for all experiments.

Peripheral blood mononuclear cell (PBMC) isolation and culture

Peripheral venous blood (100 mL) was drawn from each of the patients at time-points remote from the trial of oral GC therapy and 6 h following a dose of inhaled GC and was added to preservative-free heparin in a sterile fashion. After mixing with an equal volume of medium, 30 mL aliquots of diluted blood were layered onto 20 mL aliquots of Ficoll-Paque (Pharmacia, Uppsala, Sweden) in 50 mL sterile conical tubes (Falcon; Becton Dickinson, Cowley, UK). After centrifuging (400 × g for 20 min at 20°C), PBMCs were removed from the plasma/Ficoll interface with gentle suction, transferred to sterile polystyrene universal containers, and washed twice with medium.

Effects of drugs on the proliferative response of T-lymphocytes

PBMC were resuspended in medium at 4×10⁶ cells·mL⁻¹. Aliquots (100 µL) of this cell suspension, with or without added PHA or anti-CD3, were added to 20 µL aliquots of serially diluted drug solutions or vehicle control in triplicate in sterile 96-well round-bottomed culture plates (Cel-Cult; Sterilin, Hounslow, UK), and medium was added to produce a final volume of 200 µL per well. PBMCs were removed from the plasma/Ficoll interface with gentle suction, transferred to sterile polystyrene universal containers, and washed twice with medium.

Table 1. – Clinical characteristics of glucocorticoid sensitive and resistant asthmatics

<table>
<thead>
<tr>
<th>Age yrs</th>
<th>Sex</th>
<th>Therapy*</th>
<th>FEV1 at baseline</th>
<th>∆FEV1 after β2-agonist‡</th>
<th>∆FEV1 after prednisolone‡</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>µg·day⁻¹</td>
<td>% pred</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Sensitive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>F</td>
<td>BDP 2000</td>
<td>38</td>
<td>29</td>
<td>42</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>BDP 800</td>
<td>67</td>
<td>43</td>
<td>30</td>
</tr>
<tr>
<td>70</td>
<td>F²</td>
<td>BDP 1500</td>
<td>69</td>
<td>53</td>
<td>47</td>
</tr>
<tr>
<td>34</td>
<td>F</td>
<td>BDP 1500</td>
<td>62</td>
<td>34</td>
<td>31</td>
</tr>
<tr>
<td>63</td>
<td>F</td>
<td>BDP 2000</td>
<td>29</td>
<td>22</td>
<td>61</td>
</tr>
<tr>
<td>49</td>
<td>F</td>
<td>BDP 2000</td>
<td>48</td>
<td>22</td>
<td>32</td>
</tr>
<tr>
<td>49</td>
<td>M</td>
<td>BDP 2000</td>
<td>64</td>
<td>33</td>
<td>38</td>
</tr>
<tr>
<td>Resistant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>F</td>
<td>BDP 2000</td>
<td>67</td>
<td>42</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ipra 2000</td>
<td>40</td>
<td>24</td>
<td>-19</td>
</tr>
<tr>
<td>62</td>
<td>M</td>
<td>BDP 3000</td>
<td>21</td>
<td>16</td>
<td>6.7</td>
</tr>
<tr>
<td>55</td>
<td>F</td>
<td>BDP 2000</td>
<td>34</td>
<td>23</td>
<td>1.8</td>
</tr>
<tr>
<td>62</td>
<td>M</td>
<td>BDP 2000</td>
<td>68</td>
<td>60</td>
<td>7.6</td>
</tr>
<tr>
<td>48</td>
<td>F</td>
<td>BDP 600</td>
<td>56</td>
<td>43</td>
<td>1.7</td>
</tr>
<tr>
<td>32</td>
<td>F</td>
<td>BDP 1000</td>
<td>44</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>69</td>
<td>M</td>
<td>Bud 1600</td>
<td>66</td>
<td>17</td>
<td>6.7</td>
</tr>
<tr>
<td>70</td>
<td>F</td>
<td>BDP 2000</td>
<td>68</td>
<td>16</td>
<td>1.6</td>
</tr>
<tr>
<td>68</td>
<td>F</td>
<td>BDP 2000</td>
<td>68</td>
<td>16</td>
<td>1.6</td>
</tr>
</tbody>
</table>

*: therapy (inhaled or oral) at the time of the trial of oral prednisolone (see Methods). All patients were receiving inhaled β2-agonists. Doses represent total daily doses. #: change in baseline FEV1 after nebulized salbutamol 5 mg expressed as a percentage of the baseline value; ‡: change in baseline FEV1 after trial of oral prednisolone therapy (see Methods) expressed as a percentage of the baseline value. Bud: budesonide; Ipra: ipratropium bromide; Theo: theophylline-based preparation. For further definitions see legend to table 1.
PBMC pellets were reconstituted in 5 mL phosphate buffered saline purchased from Amersham. All solvents were of high purity. Dexamethasone, beclomethasone dipropionate, budesonide and fluticasone 17α-propionate in the concentration range $10^{-11}$ to $10^{-6}$ mol·L$^{-1}$ suppressed proliferation of PHA or anti-CD3 stimulated peripheral blood T-lymphocytes from both GC sensitive and resistant asthma patients in a dose-dependent fashion (figs. 1 and 2). The effects of these drugs were compared for each patient in contemporaneous experiments. Over a wide range of drug concentrations, T-lymphocytes from the patients with GC resistant asthma were less sensitive to inhibition with all four drugs as compared with those from sensitive patients using both the PHA and anti-CD3 stimuli (figs. 1 and 2). No proliferation was observed in the absence of PHA or anti-CD3, whether or not drugs were present (data not shown). Ethanol diluent control experiments showed no effect on T-lymphocyte proliferation at the concentrations used in the lowest drug dilutions (data not shown). Cell viability was maintained (>95% by trypan blue exclusion) throughout the duration of the experiments. Budesonide and fluticasone 17α-propionate, but not beclomethasone dipropionate, were more potent than dexamethasone in terms of the median inhibitory concentrations (IC50) of these drugs required to inhibit PHA-induced proliferation of T-lymphocytes from GC sensitive asthmatics (IC50): dexamethasone $6.5 \times 10^{-8}$ mol·L$^{-1}$; beclomethasone $1.4 \times 10^{-8}$ mol·L$^{-1}$; budesonide $2.1 \times 10^{-8}$ mol·L$^{-1}$ (p<0.002 vs dexamethasone); fluticasone $3.4 \times 10^{-10}$ mol·L$^{-1}$ (p<0.001 vs dexamethasone); (see also fig. 1). This was only evident for fluticasone with the anti-CD3 stimulus (fig. 2).
Fig. 1. Inhibition of phytohaemagglutinin (PHA)-induced proliferation of peripheral blood T-lymphocytes from glucocorticoid sensitive (●; n=7) and resistant (■; n=9) asthmatics by a) dexamethasone, b) budesonide, c) beclomethasone dipropionate and d) fluticasone 17α-propionate (10⁻¹¹ to 10⁻⁶ mol·L⁻¹) in vitro. Points marked X on the abscissae represent the approximate median inhibitory concentration (IC₅₀) for T-lymphocyte proliferation for each drug in the sensitive patients. Graphs show mean± SEM proliferation in the presence of drug expressed as a percentage of that observed in the presence of the medium (no drug) control. *: p<0.05; **: p<0.01 (between group comparisons using Mann-Whitney U-test).

Fig. 2. Inhibition of anti-CD3-induced proliferation of peripheral blood T-lymphocytes from glucocorticoid sensitive (●; n=7) and resistant (■; n=9) asthmatics by a) dexamethasone, b) budesonide, c) beclomethasone dipropionate and d) fluticasone 17α-propionate (10⁻¹¹ to 10⁻⁶ mol·L⁻¹) in vitro. Points marked X are explained in the legend to figure 1.
Steroid metabolism by T-lymphocytes from GC sensitive and resistant asthmatics

Metabolism of tritiated progesterone by cellular extracts of PHA-stimulated peripheral blood T-lymphocytes from six GC sensitive and eight resistant asthmatics was studied by HPLC as described in the Methods. Figure 3 shows the pattern of chromatographic tritium peaks produced following incubation of the cellular extracts from one typical patient with tritiated progesterone for 5 h and 24 h. This pattern of peaks was observed in all subjects studied, whether GC sensitive or resistant. The HPLC analysis indicated that there were at least seven progesterone-related chromatographic peaks produced in the incubations containing the NADPH regenerating system, including peaks A, B and C which co-chromatographed with the progesterone, 20α- and 17α-hydroxyprogesterone standards, respectively (figs. 3 and 4), two peaks (D and E) which were less polar than progesterone and two peaks (F and G) which were more polar than progesterone (fig. 3). Major products B (20α-hydroxyprogesterone) and D were seen in the presence of the NADPH regenerating system but not in control incubations in the absence of co-factors. Peaks C, E, F and G were seen both in the presence and absence of the NADPH regenerating system. None of these peaks was present in the initial stock of tritiated progesterone.

As measured by comparing the rate of disappearance of tritiated progesterone with the rate of appearance of tritiated 20α-hydroxyprogesterone during the first 5 h of the incubation period when both rates were approximately linear (table 2), 20α-hydroxylation of progesterone accounted for only 14–25% of the total turnover.

Table 2. – Rates of production of 20α-hydroxyprogesterone and metabolism of progesterone by PMBC homogenates of six GC sensitive and eight GC resistant asthmatics

<table>
<thead>
<tr>
<th></th>
<th>Rate of production of 20α-hydroxyprogesterone pmol·10^(-7)·cells·h^(-1)</th>
<th>Rate of decline in progesterone pmol·10^(-7)·cells·h^(-1)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rate of production</td>
<td>Rate of decline</td>
</tr>
<tr>
<td></td>
<td>pmol·10^(-7)·cells·h^(-1)</td>
<td>pmol·10^(-7)·cells·h^(-1)</td>
</tr>
<tr>
<td></td>
<td>2.0</td>
<td>18.1</td>
</tr>
<tr>
<td></td>
<td>2.1</td>
<td>11.5</td>
</tr>
<tr>
<td></td>
<td>2.0</td>
<td>11.4</td>
</tr>
<tr>
<td></td>
<td>1.67</td>
<td>10.6</td>
</tr>
<tr>
<td></td>
<td>1.32</td>
<td>8.6</td>
</tr>
<tr>
<td></td>
<td>0.78</td>
<td>12.0</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td>1.65†</td>
<td>12.03†</td>
</tr>
<tr>
<td><strong>SEM</strong></td>
<td>0.21</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>Resistant</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rate of production</td>
<td>Rate of decline</td>
</tr>
<tr>
<td></td>
<td>pmol·10^(-7)·cells·h^(-1)</td>
<td>pmol·10^(-7)·cells·h^(-1)</td>
</tr>
<tr>
<td></td>
<td>4.9</td>
<td>17.9</td>
</tr>
<tr>
<td></td>
<td>7.1</td>
<td>15.9</td>
</tr>
<tr>
<td></td>
<td>2.8</td>
<td>12.6</td>
</tr>
<tr>
<td></td>
<td>4.2</td>
<td>13.3</td>
</tr>
<tr>
<td></td>
<td>0.79</td>
<td>8.4</td>
</tr>
<tr>
<td></td>
<td>1.31</td>
<td>10.0</td>
</tr>
<tr>
<td></td>
<td>1.85</td>
<td>9.5</td>
</tr>
<tr>
<td></td>
<td>0.66</td>
<td>6.0</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td>2.95†</td>
<td>11.7†</td>
</tr>
<tr>
<td><strong>SEM</strong></td>
<td>0.81</td>
<td>1.41</td>
</tr>
</tbody>
</table>

†: homogenates were incubated with tritiated progesterone, and the incubation mixes were sampled at intervals (see Methods). Figures represent standardized rate of appearance of 20α-hydroxyprogesterone and decline of progesterone over the first 5 h of incubation when the curves were approximately linear (see Methods). PMBC: peripheral blood mononuclear cells; GC: glucocorticoid. *p<0.01, sensitive vs resistant, (Mann-Whitney U-test).
Fig. 5. – Inhibition of phytohaemagglutinin (PHA)-induced proliferation peripheral blood T-lymphocytes from glucocorticoid (GC) sensitive (●; n=7) and resistant (■; n=9) asthmatics by dexamethasone, cyclosporin A, FK506 (tacrolimus) and mycophenolate mofetil (10^{-11} to 10^{-6} mol·L^{-1} [cyclosporin A 10^{-8} to 10^{-6} mol·L^{-1}]) in vitro. Points X on the abscissae represent the approximate proliferation IC_{50} concentrations for each drug in the sensitive patients. Graphs show mean±SEM proliferation in the presence of drug expressed as a percentage of that observed in the presence of medium control. IC_{50}: median inhibitory concentration. *: p<0.05; **: p<0.01 (Mann-Whitney U-test).

Fig. 6. – Inhibition of anti-CD3-induced proliferation of peripheral blood T-lymphocytes for GC sensitive (●; n=7) and resistant (■; n=9) asthmatics by dexamethasone, cyclosporine A, FK506 (tacrolimus) and mycophenolate mofetil (10^{-11} to 10^{-6} mol·L^{-1}) in vitro. Graphs show mean±SEM proliferation in the presence of drug expressed as a percentage of that observed in the presence of medium control; *: p<0.05; **: p<0.01 (Mann-Whitney U-test). Points X are explained in the legend to figure 5.
in T-lymphocytes both from GC sensitive and resistant asthmatics. The mean rates of 20α-hydroxylation and total metabolism of progesterone by T-lymphocytes from the GC sensitive and resistant patients were not significantly different (p>0.1 in each case) (table 2).

**Discussion**

In previous studies, we have demonstrated that peripheral blood T-lymphocytes from asthmatic patients clinically resistant to GC therapy are more refractory to the antiproliferative effects of dexamethasone at therapeutically relevant concentrations as compared with cells from GC sensitive asthmatics in vitro [10, 22]. In this study, we have extended this observation to demonstrate a similar differential sensitivity to GCs commonly used for asthma therapy. We have also addressed the possibility that this difference in GC responsiveness might reflect differing rates of intracellular metabolism of steroids by T-lymphocytes from clinically sensitive and resistant asthmatics.

Firstly, we reasoned that if GC resistance arises from variable intracellular metabolism of these drugs by T-lymphocytes, then GCs with differing molecular structures might be differentially sensitive to this process. The data indicate, however, that peripheral blood T-lymphocytes from GC resistant asthmatics activated both with PHA and anti-CD3 are more refractory, compared with those from sensitive patients, to a variety of GCs in current therapeutic use. This suggests that GC resistance does not depend on the precise structure of the GC molecule itself, and also that asthmatics clinically resistant to prednisolone therapy are also likely to be resistant to therapy with other existing antiasthma GCs. It could be argued that it is at least conceivable that therapy of GC resistant asthmatics with topically administered GCs with high ligand binding affinity and prolonged tissue retention, such as fluticasone, might be of some clinical benefit, particularly if these drugs were to attain high concentrations in the bronchial mucosa. Whilst, it is difficult to entirely refute such an argument, it is noteworthy that this necessitates the presumption that the refractoriness of T-lymphocytes from GC resistant asthmatics to GC inhibition is attributable to a reduced binding affinity of the GC receptor in these cells for its ligand, as has been postulated by some investigators [15, 16]. These investigators noted a reduced receptor binding affinity (Kd) for dexamethasone binding (approximately 40 nmol·L⁻¹ as compared with 5 nmol·L⁻¹ in normal controls) in T-lymphocytes from a subset of patients with GC resistant asthma. The present data clearly indicate, however, that the dexamethasone IC₅₀ for proliferation of T-lymphocytes from these patients exceeds 1,000 nmol·L⁻¹ (fig. 1). At this ligand concentration, the GC receptors even in T-lymphocytes from GC resistant asthmatics would be expected to be >95% saturated, and yet the refractoriness to GC inhibition is still apparent. For this reason, we believe that this phenomenon is of questionable physiological significance, and that the presence of ligands with higher GC receptor binding affinity, even at high concentrations, could further increase receptor saturation by only a small degree. Similarly, it is not clear whether or not the previously reported reduced DNA binding of the GC receptor/ligand complex in T-lymphocytes from GC resistant patients [18] would be enhanced in the presence of ligands of higher binding affinity.

Secondly, steroid metabolism was measured in peripheral blood T-lymphocytes from GC sensitive and resistant asthmatics. Progesterone was chosen, rather than a GC for this purpose since this steroid is a well-established marker for 20α-HSDH activity and we wished to compare the data obtained with previous studies in the literature suggesting that 20α-hydroxylation is a major metabolic pathway for steroid inactivation both in murine and human T-lymphocytes [19, 20, 23]. Furthermore, previous studies have suggested that 20α-HSDH activity was higher in T-lymphocytes relatively resistant to GC inhibition [19, 20]. The present data (table 2) indicate, however, that 20α-hydroxyprogesterone was not the predominant initial metabolite, accounting for only 14–25% of the total progesterone turnover, and implying that 20α-hydroxylation is not rate-limiting for steroid deactivation in human T-lymphocytes. It would appear that this pathway of steroid metabolism is one of several in T-lymphocytes from asthmatic patients.

The HPLC analyses (figs. 3 and 4) indicated that there were at least seven progesterone-related chromatographic peaks produced in the incubations containing the NADPH regenerating system, three of which were characterized by co-chromatography with standards. Metabolism of progesterone by other animal and human tissues has been reported to result in the production of metabolites hydroxylated at the 16α, 17α, 20α and 21α positions, androstenedione, 5α-dihydroprogesterone and 3β, 5α-tetrahydroprogesterone [24–28]. It is possible that some of the chromatographic peaks observed correspond to these metabolites. Further, more detailed investigations would be required to identify all the chromatographic peaks generated from these T-lymphocytes. In view of the multiple metabolites produced, and our evidence that steroid 20α-hydroxylation was not rate-limiting, it was considered more appropriate to compare the
overall rates of metabolism of progesterone itself in
the T-lymphocytes from the GC sensitive and resistant
asthmatic patients (table 2). This comparison indicated
that there was no significant difference between the two
patient groups, implying that GC resistance cannot be
attributed to increased steroid metabolism within the
T-lymphocyte. Finally, it should be noted that these ex-
periments were performed on homogenates of PBMC
rather than T-lymphocytes. Although T-lymphocytes
comprise the majority of cells in PBMC (typically 80–
90%), they may contain up to 10% monocytes and a
small minority (typically <5%) of B-lymphocytes. We
consider it unlikely, therefore, that the total proges-
terone metabolism by PBMC could have been influ-
enced predominantly by non-T-lymphocytes, although it
is certainly possible that some of the observed meta-
bolites may have arisen from cells other than T-lym-
phocytes.

Thirdly, we wished to compare the effects of other
immunosuppressive drugs for their inhibitory effects on
T-lymphocytes from GC sensitive and resistant asth-
matics. We reasoned that drugs which inhibit T-lym-
phocytes by mechanisms distinct from those of GC might
inhibit T-lymphocytes from GC refractory asthmatics in
vitro. CsA and FK506 (tacrolimus) bind to intracellu-
lar proteins termed immunophilins The drug/immuno-
philin complexes then bind to and inhibit calcineurin,
a serine/threonine phosphatase which dephosphory-
lates the cytoplasmic subunit of the IL-2 transcriptional
regulator nuclear factor of activated T-cells (NF-AT),
allowing it to migrate into the cell nucleus [28–30]. My-
cophenolate mofetil is de-esterified to mycophenolic acid
by human cells. This is a potent and specific inhibitor
of the enzyme, inosine monophosphate dehydrogenase,
which is required by T-lymphocytes and B-lymphocytes
for the de novo synthesis of guanosine nucleotides. It
is, thus, a selective suppressor both of T- and B-lym-
phocyte proliferation [31]. All of these drugs have been
used clinically for immunosuppression, principally for
prevention of rejection of allografts.

As shown in figures 5 and 6, CsA, FK506 (tacrolimus)
and mycophenolate mofetil inhibited PHA- or anti-
CD3-induced proliferation of T-lymphocytes from GC
sensitive and resistant asthmatics with equivalent pot-
ency and at IC50 concentrations considerably less than
those for all of the GCs tested in the GC resistant asth-
matics. This supports our hypothesis that the observed
cellular defect in T-lymphocytes from resistant asth-
matics is confined to GC-mediated inhibitory mecha-
nisms. The data relating to CsA confirm our previous
reports [21, 22]. The experiments described in figures
1 and 2, and 5 and 6, which were performed on the same
subjects at different times, confirm the repeatability of
the measurements within individual patients in the short
term, as demonstrated previously [23]. We have also
shown previously [22] that the range of concentrations
of the drugs employed in this study encompasses the
therapeutic range, although the optimal therapeutic con-
centration of mycophenolate mofetil has yet to be estab-
lished. Although it is not possible to compare the local
concentrations of these drugs achieved in the asthmas-
tic bronchial mucosa by oral therapy (or topical therapy
in the case of GCs), these data are at least compatible
with the hypothesis that these immunosuppressive agents
may be useful at therapeutic concentrations for the ther-
apy of GC resistant asthmatics, whose T-lymphocytes
are not inhibited by currently available GCs at dosages
considered therapeutically acceptable.

In summary, we have further investigated the mech-
anism whereby T-lymphocytes from GC resistant asth-
matics are resistant to the inhibitory effects of GCs in
vitro. We have shown that this phenomenon is unlikely
to be dependent on variable intracellular metabolism
of GCs by T-lymphocytes, since; 1) it is observed with
GCs of differing structures; and 2) there is no evidence
of enhanced steroid metabolism in resistant cells. Our
data suggest that T-lymphocytes from GC resistant asth-
matics are less likely to be inhibited by therapeutic con-
centrations [10, 22] of GCs currently employed for
asthma therapy and, furthermore, that other anti-T-lym-
phocyte drugs, used alone or in combination, may be
effective for the therapy of GC resistant asthma. We
recently showed in two double-blind trials that CsA
therapy improved lung function and reduced the fre-
cuency of disease exacerbations [32], and allowed sig-
nificant reduction of oral GC therapy while improving
lung function [33], in groups of patients with chronic,
severe, GC-dependent asthma, although this has not
been confirmed in a third study [34]. These data sug-
gest that the antiproliferative effects of CsA on T-lym-
phocytes from asthmatics may be a poor predictor of
clinical efficacy (which is not to say that CsA is clini-
cally ineffective). Further studies may clarify whether
or not potentially more relevant in vitro assays (such as
inhibition of secretion of asthma-relevant cytokines) may
better predict clinical response. Whatever the case, the
current findings suggest that clinical studies to assess
drugs, such as FK506 (tacrolimus) and mycophenolate
mofetil, for their efficacy and safety in the therapy of
asthma would be justified, especially in those patients
with glucocorticoid refractory disease.

References

of activated T-lymphocytes and eosinophils in bronchial
biopsies in stable atopic asthma. Am Rev Respir Dis
2. Corrigan CJ, Hartnell A, Kay AB. T-lymphocyte activ-
ation in acute severe asthma. Lancet 1988; ii: 1129–
1132.
3. Walker C, Kaegi MK, Braun P, Blaser K. Activated T-
cells and eosinophils in bronchoalveolar lavages from
subjects with asthma correlated with disease severity. J
4. Lassalle P, Sergant M, Delneste Y, et al. Levels of solu-
ble IL-2 receptor in plasma from asthmatics: correlations
with blood eosinophilia, lung function and glucocortic-
5. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation
in acute severe asthma: relationship to disease severity
in mucosal bronchial biopsies from asthmatic subjects.
or not potentially more relevant in vitro assays (such as
inhibition of secretion of asthma-relevant cytokines) may
better predict clinical response. Whatever the case, the
current findings suggest that clinical studies to assess
drugs, such as FK506 (tacrolimus) and mycophenolate
mofetil, for their efficacy and safety in the therapy of
asthma would be justified, especially in those patients
with glucocorticoid refractory disease.

References

of activated T-lymphocytes and eosinophils in bronchial
biopsies in stable atopic asthma. Am Rev Respir Dis
2. Corrigan CJ, Hartnell A, Kay AB. T-lymphocyte activ-
ation in acute severe asthma. Lancet 1988; ii: 1129–
1132.
3. Walker C, Kaegi MK, Braun P, Blaser K. Activated T-
cells and eosinophils in bronchoalveolar lavages from
subjects with asthma correlated with disease severity. J
4. Lassalle P, Sergant M, Delneste Y, et al. Levels of solu-
ble IL-2 receptor in plasma from asthmatics: correlations
with blood eosinophilia, lung function and glucocortic-
5. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation
in acute severe asthma: relationship to disease severity
in mucosal bronchial biopsies from asthmatic subjects.
or not potentially more relevant in vitro assays (such as
inhibition of secretion of asthma-relevant cytokines) may
better predict clinical response. Whatever the case, the
current findings suggest that clinical studies to assess
drugs, such as FK506 (tacrolimus) and mycophenolate
mofetil, for their efficacy and safety in the therapy of
asthma would be justified, especially in those patients
with glucocorticoid refractory disease.

References

of activated T-lymphocytes and eosinophils in bronchial
biopsies in stable atopic asthma. Am Rev Respir Dis
2. Corrigan CJ, Hartnell A, Kay AB. T-lymphocyte activ-
ation in acute severe asthma. Lancet 1988; ii: 1129–
1132.
3. Walker C, Kaegi MK, Braun P, Blaser K. Activated T-
cells and eosinophils in bronchoalveolar lavages from
subjects with asthma correlated with disease severity. J
4. Lassalle P, Sergant M, Delneste Y, et al. Levels of solu-
ble IL-2 receptor in plasma from asthmatics: correlations
with blood eosinophilia, lung function and glucocortic-
5. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation
in acute severe asthma: relationship to disease severity
in mucosal bronchial biopsies from asthmatic subjects.
or not potentially more relevant in vitro assays (such as
inhibition of secretion of asthma-relevant cytokines) may
better predict clinical response. Whatever the case, the
current findings suggest that clinical studies to assess
drugs, such as FK506 (tacrolimus) and mycophenolate
mofetil, for their efficacy and safety in the therapy of
asthma would be justified, especially in those patients
with glucocorticoid refractory disease.


